Advertisement

Clinical Pharmacokinetics

, Volume 58, Issue 5, pp 685–685 | Cite as

Correction to: Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials

  • Yulan QiEmail author
  • Kathleen McKeever
  • Julie Taylor
  • Christine Haller
  • Wenjie Song
  • Simon A. Jones
  • Jack Shi
Correction

1 Correction to: Clinical Pharmacokinetics  https://doi.org/10.1007/s40262-018-0721-y

Introduction section, para 3, lines 2–4 which previously read:

In an open-label, phase I/II, dose-finding trial (ClinicalTrials.gov identifier: NCT02418455),…

should read:

In an open-label, phase I/II, dose-finding trial (ClinicalTrials.gov identifier: NCT01856218),…

The original article was corrected.

Copyright information

© The Author(s) 2019

Authors and Affiliations

  • Yulan Qi
    • 1
    • 2
    Email author
  • Kathleen McKeever
    • 1
  • Julie Taylor
    • 1
  • Christine Haller
    • 1
  • Wenjie Song
    • 1
    • 3
  • Simon A. Jones
    • 4
  • Jack Shi
    • 1
  1. 1.Ultragenyx Pharmaceutical Inc.NovatoUSA
  2. 2.BioMarin Pharmaceutical Inc.NovatoUSA
  3. 3.Ascendis Pharmaceutical Inc.Palo AltoUSA
  4. 4.Willink Unit, Manchester Centre for Genomic Medicine, Saint Mary’s Hospital, Manchester and Academic Health Sciences CentreCentral Manchester University Hospitals NHS Foundation TrustManchesterUK

Personalised recommendations